MicroRNA immunomodulating therapeutics

Blood. 2020 Jan 16;135(3):155-156. doi: 10.1182/blood.2019004106.

Abstract

In this issue of Blood, Su et al employ an elegant microRNA (miRNA or miR) conjugation strategy to unleash the potential of targeted miRNA therapeutics, and, as a proof of concept, effectively counteract common inflammatory and myeloid disease states.

Publication types

  • Comment

MeSH terms

  • Humans
  • Inflammation
  • Leukemia*
  • MicroRNAs*
  • Myeloid Progenitor Cells
  • NF-kappa B

Substances

  • MicroRNAs
  • NF-kappa B